RxDoctor Payments DataLook up a doctor →

Kent Ta, MD

Rheumatology · Bellevue, WANPI 1508853003

Payments from drug & device makers

$21,582in general payments, 2019–2025

Across 1,004 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Johnson & Johnson$3K
  • AbbVie$2K
  • Pfizer$2K
  • UCB, Inc.$1K
  • AstraZeneca$1K
  • plus $8K from 47 others

What the payments were for

  • Food & beverage$21,25598%
  • Education$3282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,582 in reported general payments places this provider in the 80th percentile of 157 rheumatology providers in Washington.

See all rheumatology providers in Washington

Medicare billing

Part B allowed, 2024
$1,699,762
Medicare patients
388
Services billed
106,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept22$220,635
EnbrelEtanercept23$187,965
Xeljanz XrTofacitinib Citrate14$90,875
Actemra ActpenTocilizumab13$90,488
RinvoqUpadacitinib11$79,368
SimponiGolimumab11$67,677
Hydroxychloroquine Sulfate272$13,913
MethotrexateMethotrexate Sodium379$10,818
OtrexupMethotrexate/Pf12$9,224
Prednisone425$4,607
Duloxetine Hcl129$3,499
Tramadol Hcl332$3,435
Leflunomide58$3,213
Cevimeline Hcl15$2,834
Acetaminophen-CodeineAcetaminophen With Codeine109$2,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$3,367$187,96523 claims
AbbVieRinvoq$2,222$79,36811 claims
Johnson & JohnsonSimponi$2,848$67,67711 claims
Antares Pharma, Inc.Otrexup$69$9,22412 claims
Scilex Pharmaceuticals Inc.Colchicine$43$2,03462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 157 rheumatology providers in Washington.

Other rheumatology in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →